Berlin, November 01, 2010 - As the company disclosed today, the claim against MOLOGEN AG was rejected and the claimant sentenced to reimburse costs. Background was the dispute about returning a product license for the region of India for the cell-based gene therapy against cancer developed by MOLOGEN AG.
CEO Dr. Matthias Schroff expresses his satisfaction: “The arbitration court confirmed with this decision that our assessment of the procedure was correct from the outset”. (see press release from 19/08/2009)
The issued arbitration decision has the effect of a legally binding court judgement.
About MOLOGEN AG
Die MOLOGEN AG, a German biopharmaceutical company with headquarters in Berlin specializes in the research and development of innovative medications on the basis of DNA structures. The activities focus on numerous product developments which are relevant to the immune system; on the one hand vaccines against infectious diseases and on the other hand cancer medications. MOLOGEN AG is globally one of the few biotechnology companies with well tolerated DNA-based cancer treatment in the clinical development phase.
The stocks of MOLOGEN AG are listed in the Prime Standard of the German stock exchange. (ISIN DE0006637200).
MOLOGEN AG PRESS SERVICE Prof. Peter W. Huebner Director of Corporate Communications
Tel: +49 - 30 - 84 17 88 - 38 Tel: +49 - 30 - 84 17 88 - 50 huebner@mologen.com
MOLOGEN AG: Joerg Petraß Tel: +49 - 30 - 84 17 88 - 13 Tel: +49 - 30 - 84 17 88 - 50 investor@mologen.com
Note about risk for future predictions Certain information in this report contains forward-looking statements or the corresponding statements with negation or versions deviating from this or comparable terminology. These are described as forward-looking statements. In addition, all of the information given here that refers to planned or future results of business areas, key financial figures, developments of the financial situation or other financial figures or statistical data, is to be understood as such forward- looking statements. The company points out to investors that they should not rely on these forward-looking statements as predictions about actual future events. The company is not obligated and refuses to accept any liability for the forward- looking statements and has no obligation to update such statements in order to accurately reflect the current situation..
Memberships in associations: BIO Deutschland e.V. | DECHEMA - Society for chemical technology and biotechnology e.V. | German industrial association of biotechnology (DIB) | Association for the Promotion of Science and Humanities in Germany | Association of German biotechnology companies (VBU) | Association of researching manufacturers of pharmaceuticals e.V. (VFA) | Association of the chemical industry e.V. (VCI)
MIDGE®, dSLIM® and MOLOGEN® are registered trademarks of MOLOGEN AG.
